Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May;11(5):e10362.
doi: 10.15252/emmm.201910362.

Anti-VEGF-A/ANG2 combotherapy limits pathological angiogenesis in the eye: a replication study

Anne Wolf  1 , Thomas Langmann  1   2
Affiliations

Anti-VEGF-A/ANG2 combotherapy limits pathological angiogenesis in the eye: a replication study

Anne Wolf et al. EMBO Mol Med. 2019 May.

Abstract

Neovascular and inflammatory retinal diseases including wet age‐related macular degeneration (AMD) can cause severe vision loss among the elderly. Simultaneous neutralization of vascular endothelial growth factor‐A (VEGF‐A) and angiopoietin 2 (ANG2) is envisioned as a novel candidate approach to treat wet AMD with better efficacy. However, earlier published data from a genetic mouse model showed data aberrations (Regula et al, 2016). In this issue of EMBO Molecular Medicine, Foxton et al (2019) have provided compelling evidence replicating the data and confirming the overall concept that VEGF‐A/ANG2 combotherapy is effective in suppressing retinal neovascularization.

PubMed Disclaimer

Conflict of interest statement

TL serves in advisory boards for Bayer, Novartis, and Roche that develop drugs for retinal degenerative and neovascular diseases.

References

    1. Akhtar‐Schafer I, Wang L, Krohne TU, Xu H, Langmann T (2018) Modulation of three key innate immune pathways for the most common retinal degenerative diseases. EMBO Mol Med 10: e8259 - PMC - PubMed
    1. Comparison of Age‐related Macular Degeneration Treatments Trials Research Group , Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, Toth CA, Ferris FL III, Fine SL (2016) Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the comparison of age‐related macular degeneration treatments trials. Ophthalmology 123: 1751–1761 - PMC - PubMed
    1. Foxton RH, Uhles S, Grüner S, Revelant F, Ullmer C (2019) Efficacy of simultaneous VEGF‐A/ANG‐2 neutralization in suppressing spontaneous choroidal neovascularization. EMBO Mol Med 11: e10204 - PMC - PubMed
    1. Hackett SF, Wiegand S, Yancopoulos G, Campochiaro PA (2002) Angiopoietin‐2 plays an important role in retinal angiogenesis. J Cell Physiol 192: 182–187 - PubMed
    1. Kim LA, D'Amore PA (2012) A brief history of anti‐VEGF for the treatment of ocular angiogenesis. Am J Pathol 181: 376–379 - PMC - PubMed

MeSH terms

Substances